Jasper Therapeutics completes all-stock merger with Kira Pharmaceuticals
The combined company raised $132 million in a private placement and licensed out two complement assets to Mirador Therapeutics for $12 million upfront.
Jasper Therapeutics announced on July 16, 2026 that it had finished acquiring Kira Pharmaceuticals, a Cayman-incorporated company that had been developing complement therapies to treat immune-mediated diseases, structured as an all-stock transaction1. The deal closed alongside a private placement of non-voting convertible preferred stock.
The financing round was co-led by Affinity Asset Advisors and Ikarian Capital, with participation from a group of investors including Columbia Threadneedle Investments, Sirenia Capital Management, Brahma Capital, Balyasny Asset Management, SilverArc Capital, Squadron Capital Management, Nazare Partners, and Mirador Therapeutics, and is expected to generate gross proceeds of approximately $132 million1. Each share of the new preferred stock will automatically convert into 61 shares of Jasper common stock once Jasper's stockholders approve the conversion under Nasdaq rules1. The private placement is set to close on July 20, 2026, per the filing.
As part of the transaction, Kira licensed two complement-targeting drug candidates, KP-301 (a long-acting anti-C5a antibody) and KP-402 (a small-molecule C5a receptor antagonist), to Mirador Therapeutics. The licensing deal includes a $12 million upfront payment along with potential future development and sales milestone payments.1
Combined cash, including the placement and licensing proceeds but excluding any milestones, is expected to fund the combined company's operations through the second half of 2028, covering milestones such as Phase 2 renal data for KP-104, an FDA end-of-Phase 2 meeting for KP-104 in PNH, progress toward a pre-BLA meeting for briquilimab in SCID, and first-in-human data for KP-7011.
Post-transaction, former Jasper shareholders will hold about 6.68%, Kira equityholders about 49.86%, and private placement investors about 43.46% of the combined company's stock on a fully diluted basis, with total shares outstanding reaching roughly 653.6 million after the deal closes.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.